Jacob Moyer, BS

Jacob Moyer, BS, is a graduate researcher at Mayo Clinic.

Articles by Jacob Moyer, BS

Jacob Moyer, BS, graduate researcher, Mayo Clinic; Mark Tyson II, MD, MPH, urologic oncologist, associate professor, urology, Mayo Clinic Alix School of Medicine

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

ByJacob Moyer, BS,Mark D. Tyson, II, MD, MPH

May 1st 2025

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

ByJacob Moyer, BS

March 19th 2025

Jacob Moyer, BS, discusses early, real-world efficacy and safety data with nadofaragene firadenovec in BCG-unresponsive non–muscle-invasive bladder cancer.

Jacob Moyer, BS

Articles by Jacob Moyer, BS

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

Moyer on Early Efficacy Data With Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Latest Updated Articles

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL